Provided by Tiger Fintech (Singapore) Pte. Ltd.

Esperion Therapeutics

1.15
+0.150015.00%
Pre-market: 1.160.0100+0.87%08:18 EDT
Volume:5.74M
Turnover:6.40M
Market Cap:227.93M
PE:-1.42
High:1.18
Open:1.01
Low:1.00
Close:1.00
Loading ...

Esperion Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director John Craig Thompson

Reuters
·
Yesterday

Esperion appoints Craig Thompson to board of directors

TIPRANKS
·
01 Jul

Esperion Therapeutics Appoints Craig Thompson to Board of Directors, Bringing Extensive Biopharmaceutical Expertise

Reuters
·
01 Jul

CFO Benjamin Halladay Reports Disposal of Common Shares in Esperion Therapeutics Inc

Reuters
·
19 Jun

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
17 Jun

Esperion Therapeutics Inc. Concluded Annual Stockholders Meeting

Reuters
·
03 Jun

Esperion Therapeutics Settles Patent Litigation, Delays Generic NEXLETOL Until 2040

Reuters
·
02 Jun

Esperion Reaches Settlement Agreement With Second Anda Filer Not to Market Generic Version of Nexletol® (Bempedoic Acid) Prior to April 19, 2040

THOMSON REUTERS
·
02 Jun

Esperion Therapeutics Inc. to Participate in Jefferies Global Healthcare Conference in New York

Reuters
·
20 May

Esperion to Participate in Upcoming June Investor Conferences

GlobeNewswire
·
20 May

Esperion Therapeutics, Micro Labs Settle Generic Nexletol Patent Dispute

MT Newswires Live
·
12 May

Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
09 May

HLS Therapeutics: Q1 Net Loss $0.14 per Share

THOMSON REUTERS
·
08 May

HLS Therapeutics: 2025 Financial Targets Are Unchanged

THOMSON REUTERS
·
08 May

Press Release: HLS Therapeutics Announces Q1 2025 Financial Results

Dow Jones
·
08 May

HLS Therapeutics Partners With Esperion Therapeutics to Commercialize Nexletol® and Nexlizet® in Canada

THOMSON REUTERS
·
08 May

Esperion Therapeutics: Under Agreement, Esperion to Receive Upfront Payment, Near-Term Milestone & Tiered Royalties on Product Sales

THOMSON REUTERS
·
08 May

Esperion Therapeutics: to Receive Upfront Payment & Be Eligible for Milestone Payments of up to About $5 Mln With Tiered Royalties on Product Sales

THOMSON REUTERS
·
08 May

Esperion Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
07 May

Esperion Therapeutics Reports Mixed Q1 2025 Results

TIPRANKS
·
07 May